Pharmacogenomics in early-phase clinical development

Author： Burt Tal   Dhillon Savita  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.9, 2013-07, pp. : 1085-1097

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development: Designing Informative Human Pharmacology Studies

By Cohen Adam  

Clinical Pharmacokinetics, Vol. 47, Iss. 6, 2008-01 ,pp. : 373-381

Adis International

Access to resources Recommend Favorite

Nateglinide restores early-phase insulin secretion in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1272, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Economic Evaluations During Early (Phase II) Drug Development: A Role for Clinical Trial Simulations?

By Hughes D.A.   Walley T.  

PharmacoEconomics, Vol. 19, Iss. 11, 2001-11 ,pp. : 1069-1077

Adis International

Access to resources Recommend Favorite

Implications of the incidentalome for clinical pharmacogenomics

By Brothers Kyle B   Langanke Martin   Erdmann Pia  

Pharmacogenomics, Vol. 14, Iss. 11, 2013-08 ,pp. : 1353-1362

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics and Clinical R&D

By Arnold Hans Peter   Hall Susan T  

Pharmacogenomics, Vol. 6, Iss. 8, 2005-12 ,pp. : 801-806

Future Medicine

Access to resources Recommend Favorite